covid
Buscar en
Revista Colombiana de Cancerología
Toda la web
Inicio Revista Colombiana de Cancerología Descripción de una cohorte de pacientes con cáncer de mama triple-negativo sub...
Journal Information
Vol. 16. Issue 2.
Pages 91-99 (January 2012)
Share
Share
Download PDF
More article options
Vol. 16. Issue 2.
Pages 91-99 (January 2012)
Full text access
Descripción de una cohorte de pacientes con cáncer de mama triple-negativo subtipo basal-like, atendidas en el Instituto Nacional de Cancerología y en el Hospital de San José durante el periodo 2006-2008
Cohort Description of Patients with Triple-Negative Basal-Like Subtype Breast Cancer Treated at the National Cancer Institute and the San José Hospital from 2006 to 2008
Visits
3693
Óscar García1,
Corresponding author
osaga72@gmail.com

Correspondencia Óscar García Angulo, Instituto Nacional de Cancerología, Avenida 1a No. 9-85, Bogotá, D. C., Colombia. Teléfono 334 1111 ext. 5424.
, Carlos A. Ossa2, María I. Beltrán3, Miguel Cano4, Licet Villamizar5, Ana M. Arias6
1 Clinica de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia
2 Servicio de Cirugía de Seno, Clínica Las Américas, Medellín, Colombia
3 Departamento de Patología Oncológica, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia
4 Servicio de Patología, Fundación Universitaria Hospital San José, Bogotá, D. C., Colombia
5 Grupo de Investigación Clínica, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia
6 Servicio de Seno, Clínica Colsubsidio, Bogotá, D. C, Colombia
This item has received
Article information
Resumen
Objetivos

Establecer la prevalencia y describir las características clínico-patológicas de las pacientes con cáncer de mama triple-negativo subtipo (basal-like y no basal-like) mediante técnicas de inmunohistoquímica que fueron atendidas en el Instituto Nacional de Cancerología (INC) y el Hospital San José (HSJ) durante el periodo 2006- 2008.

Métodos

Se realizó un estudio descriptivo de corte transversal, en mujeres mayores de 17 años con diagnóstico histológico confirmado de adenocarcinoma de mama. Se excluyó a las pacientes cuyos bloques de parafina no se conservaron, o a quienes no se les pudieron realizar todos los marcadores inmunohistoquímicos requeridos por el estudio, y se procedió a realizar los marcadores de inmunohistoquímica considerados en el estudio (EFGR, CK5, CK6, S100, P65, CK 14). Se procesaron las muestras siguiendo las recomendaciones de la casa matriz. Se procedió a analizar la información con el programa estadístico Stata10.

Resultados

Un total de 1922 casos de cáncer de mama invasor fueron diagnosticados en el periodo comprendido 2006-2008 de los cuales fueron identificados 154 casos de tumores triple negativos (RE negativo, RP negativo, HER-2 Negativo). De estos casos se obtuvo información completa de 84 casos. 50 (59,52%) casos corresponden al tipo basal-like, mientras que 34 (40,48%) corresponden a tumores no basal-like.

Conclusiones

El presente estudio es el primero en Colombia que busca determinar mediante inmunohistoquímica la prevalencia del cáncer de mama triple-negativo de tipo basal-like en población colombiana; se halló así una prevalencia del 8,01%, porcentaje que se encuentra por debajo de lo reportado en la literatura mundial (11,9%-25%).

Palabras clave:
Neoplasias de la mama
citoqueratina
inmunohistoquímica
prevalencia
Abstract
Objectives

To use immunohistochemistry to provide a description of and to ascertain the prevalence of clinical-pathological characteristics in patients with triple-negative (basal-like and non basal-like) subtype breast cancer treated at the National Cancer Institute (NCI) and the San José Hospital (SJH) from 2006 to 2008.

Methods

A descriptive cross sectional study was carried out among women over 17 years of age with confirmed diagnosis of breast adenocarcinoma. Patients whose paraffin blocks were not preserved and those on whom it was not possible to carry out the entirety of the immunohistochemical markers requisite for this study were excluded before collection of the immunohistochemical markers considered essential for this study (EFGR, CK5, CK6, S100, P65, CK 14) was performed. Samples were processed according to manufacturer's instructions; information was analyzed with Stata 10 software.

Results

A total of 1,922 invasive breast cancer cases were diagnosed from 2006 to 2008, 154 of which were triple-negative (ER negative, PR negative, HER-2 negative). Complete information was obtained in 84 of these cases: 50 cases (59.52%) were basal like and 34 cases (40.48%) were non basal-like tumors.

Conclusions

This study, the first in Colombia which seeks to determine through immunohistochemistry the prevalence of triple-negative basal-like breast cancer in the Colombian population, found said tumor prevalence to be at 8.01%, which is below that reported in worldwide literature (11.9%-25%).

Key words:
Breast neoplasms
keratins
immunohistochemistry
prevalence
Full text is only aviable in PDF
Referencias
[1.]
American Cancer Society. Overview: Breast Cancer [internet]. 2006 [citado: 15/01/2012. Disponible en: www.cancer.org.
[2.]
Ferlay J, Bray F, Pisan P, et al. International Agency for Research on Cancer. GLOBOCAN 2008. IARC. Cancer Database, No. 5, version 2.
[3.]
Instituto Nacional de Cancerologia (INC).
Anuario Estadistico 2008.
INC, (2009),
[4.]
C.M. Perou, T. Sorlie, M.B. Eisen, et al.
Molecular portraits of human breast tumour.
Natur, 406 (2000), pp. 747-752
[5.]
L.J. Van’t Veer, H. Dai, M.J. van de Vijver, et al.
Gene expression profiling predicts clinical outcome of breast cance.
Nature, 415 (2002), pp. 530-536
[6.]
L.A. Carey, C.M. Perou, C.A. Livasy, et al.
Race breast cancer subtypes survival in the Carolina Breast Cancer Stud.
JAMA, 295 (2006), pp. 2492-2502
[7.]
M. Van de Rijn, C.M. Perou, R. Tibshirani, et al.
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcom.
Am J Pathol, 161 (2002), pp. 1991-1996
[8.]
E.A. Rakha, D.S. Tan, W.D. Foulkes, et al.
Are triple-negative tumours and basal-like breast cancer synonymous.
Breast Cancer Res, 9 (2007), pp. 404
[9.]
R. Moll, R. Krepler, W.W. Franke.
Complex cytokeratin polypeptide patterns observed in certain human carcinoma.
Differentiation, 23 (1983), pp. 256-269
[10.]
C.A. Livasy, G. Karaca, R. Nanda, et al.
Phenotypic evaluation of the basal-like subtype of invasive breast carcinom.
Mod Pathol, 19 (2006), pp. 264-271
[11.]
A. Bosch, P. Eroles, R. Zaragoza, et al.
Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of researc.
Cancer Treat Rev, 36 (2010), pp. 206-215
[12.]
S.R. Wellings, P. Roberts.
Electron microscopy of sclerosing adenosis and infiltrating duct carcinoma of the human mammary glan.
J Natl Cancer Inst, 30 (1963), pp. 269-287
[13.]
K. Sarkar, E. Kallenbach.
Myoepithelial cells in carcinoma of human breas.
Am J Pathol, 49 (1966), pp. 301-307
[14.]
T.M. Murad, D.G. Scharpelli.
The ultrastructure of medullary and scirrhous mammary duct carcinom.
Am J Pathol, 50 (1967), pp. 335-360
[15.]
S.H. Dairkee, B.H. Mayall, H.s. Smith, et al.
Monoclonal marker that predicts early recurrence of breast cancer.
Lancet, 1 (1987), pp. 514
[16.]
K. Malzahn, M. Mitze, M. Thoenes, et al.
Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinoma.
Virchows Arch, 433 (1998), pp. 119-129
[17.]
L.G. Fulford, D.F. Easton, J.S. Reis-Filho, et al.
Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breas.
Histopathology, 49 (2006), pp. 22-34
[18.]
S. Rodriguez, D. Sarrio, E. Honrado, et al.
Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinom.
Clin Cancer Res, 12 (2006), pp. 1533-1539
[19.]
C. Liedtke, C.H. Mazouni, R.H. Kenneth, et al.
Response to Neoadjuvant theraphy long-term survival in patients with triple-negative.
Breast Cancer JCO, 26 (2008), pp. 1275-1281
[20.]
F. Lara-Medina, V. Perez-Sanchez, D. Saavedra-Perez, et al.
Triple-negative breast cancer in hispanic patients: High prevalence, poor prognosis, and association with menopausal status, body mass index, and parit.
Cancer, 117 (2011), pp. 3658-3669
[21.]
C.S. Vallejos, H.L. Gomez, W.R. Cruz, et al.
Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital databas.
Clinical Breast Cancer, 10 (2010), pp. 294-300
[22.]
M. De Brot, F.A. Soares, M. Stiepcich, et al.
Basal-like breast cancers: clinicopathological features and outcom.
Rev Assoc Med Bras, 55 (2009), pp. 529-534
[23.]
Y.L. Choi, E. Oh, S. Park, et al.
Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for surviva.
BMC Cancer, 10 (2010), pp. 507
[24.]
F. Bertucci, P. Finetti, N. Cervera, et al.
How basal are triple-negative breast cancers?.
Int J Cancer, 123 (2008), pp. 236-240
[25.]
B. Kreike, M. van kouwenhove, H. Horlings, et al.
Gene expression profiling and histopathological of triplenegative/basal-like breast carcinom.
Breast Cancer Res, 9 (2007), pp. R65
[26.]
T.O. Nielsen, F.D. Hsu, K. Jensen, et al.
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinom.
Clin Cancer Res, 10 (2004), pp. 5367-5374
[27.]
W.D. Foulkes, I.E. Smith, J.S. Reis-Filho.
Triple-negative breast cancer.
Engl J N. Me, 363 (2010), pp. 1938-1948
Copyright © 2012. Instituto Nacional de Cancerología
Download PDF
Article options